Transdel Initiates Ketotransdel TM Phase 3 Clinical Program For Pain

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company developing non-invasive, topically administered medications, announced the initiation of its Phase 3 clinical program for Ketotransdel(TM), its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID") for pain.

Nanotechnology, Biomolecules And Light Unite To 'Cook' Cancer Cells

Researchers are testing a new way to kill cancer cells selectively by attaching cancer-seeking antibodies to tiny carbon tubes that heat up when exposed to near-infrared light.

Health Economic Analysis Reports That REVLIMID Is A Cost-Effective Treatment For Multiple Myeloma

Celgene Corporation (NASDAQ: CELG) announced that data presented recently at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark showed that the use of REVLIMID and dexamethasone was cost-effective with the incremental cost-effectiveness threshold ranging from ^Alb20, 000 to ^Alb30, 000 per quality adjusted life year (QALY).

Novel Compound May Treat Acute Diarrhea

In a development that may lessen the epidemic of diarrhea-related deaths among children in developing countries, scientists in the laboratory of Nobel Laureate Ferid Murad, M.D., Ph.D., at The University of Texas Health Science Center at Houston have discovered a novel compound that might lead to an inexpensive, easy-to-take treatment.

New Study Shows BENICAR R olmesartan Medoxomil Reverses Blood Vessel Damage Independent Of Blood Pressure Lowering

A new study published in the current Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension..

Blood Pressure Levels In Childhood Track Into Adulthood

High blood pressure in childhood is associated with higher blood pressure or hypertension in adulthood, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health.

SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits In Vivo Tumor Cell Proliferation

SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, announced at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, that SGI-1252, its JAK2 kinase inhibitor, prevents tumor cell proliferation in vivo (abstract #741).

Sanofi Pasteur To Donate 60 Million Doses Of H5N1 Vaccine To WHO Over 3 Years For Its Influenza Vaccine Global Stockpile

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced yesterday its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global stockpile.

Geisinger Study: Inflammatory Disease Causes Blindness

People suffering from a type of connective tissue disease characterized by inflammation of arteries in the head are three times more likely to experience blindness, new Geisinger research shows.In a study published in a recent edition of the Journal of Clinical Pathology, Geisinger researchers examined a disorder known as temporal arteritis.

Lou Gehrig's Disease Protein Found Throughout Brain, Suggesting Effects Beyond Motor Neurons

Two years ago researchers at the University of Pennsylvania School of Medicine discovered that misfolded proteins called TDP-43 accumulated in the motor areas of the brains of patients with amyotropic lateral sclerosis (ALS), or Lou Gehrig's disease.